Form 4: BioXcel Director Granted 17,000 Stock Options

BioXcel Therapeutics Director Michal Votruba was granted 17,000 stock options with an exercise price of $2.01, vesting based on service.

Summary

• Michal Votruba, a Director of BioXcel Therapeutics, Inc. (BTAI), was granted 17,000 stock options.
• The stock options have an exercise price of $2.01 per share.
• The grant date for these options was January 9, 2026.
• The options expire on January 9, 2036.
• Vesting occurs on the earlier of the first anniversary of the grant date or the day immediately prior to the next annual meeting of the Issuer's stockholders occurring after the grant date, contingent on continued service as a non-employee director.

Sentiment

Score: 6

Explanation: The grant of stock options to a director is a routine compensation event that aligns the director's interests with shareholders, generally viewed as a neutral to slightly positive corporate governance practice.

Positives

• The grant of stock options aligns the director's interests with those of shareholders, incentivizing long-term performance and value creation.

Negatives

• NA

Risks

• NA

Future Outlook

The stock options are subject to future vesting conditions, aligning the director's incentives with the company's long-term performance and strategic objectives.

Management Comments

• NA

Industry Context

The grant of stock options to a non-employee director is a standard practice in the biotechnology industry to attract and retain qualified board members, aligning their interests with long-term shareholder value creation.

Comparison to Industry Standards

• Granting stock options to non-employee directors is a common compensation practice across publicly traded companies, including those in the biotechnology sector, to incentivize performance and retention.
• The specific number of options (17,000) and exercise price ($2.01) would require comparison to peer companies of similar market capitalization and stage of development to assess if it falls within industry norms, but this filing does not provide such comparative context.

Management Changes

Corporate Governance

Legal Proceedings

• NA

Related Party Transactions

• Grant of 17,000 stock options to Michal Votruba, a non-employee director, as part of his compensation, which constitutes a related party transaction.

Stakeholder Impact

• Shareholders: Potential for future dilution if options are exercised, but also potential for improved corporate governance and performance alignment due to director incentives.
• Employees: No direct impact on general employees is indicated by this filing.

Next Steps

• The options will vest on the earlier of January 9, 2027, or the day prior to the next annual meeting of stockholders, subject to Michal Votruba's continued service as a non-employee director.

Key Dates

Keywords

BioXcel Therapeutics, BTAI, stock options, director compensation, Form 4, insider transaction, Michal Votruba